Form 4: Adaptimmune Therapeutics Executive Sells Shares to Cover Tax Obligations

John Lunger, Chief Patient Supply Officer at Adaptimmune Therapeutics, sold 5,584 American Depositary Shares (ADS) to cover tax obligations related to vested stock options.

Summary

• John Lunger, Chief Patient Supply Officer of Adaptimmune Therapeutics, sold 5,584 American Depositary Shares (ADS) on January 17, 2025.
• The sale was executed to cover tax withholding obligations and associated sale costs related to the vesting of RSU-style share options.
• The ADSs were sold at a weighted average price of $0.5808, with individual transactions ranging from $0.5797 to $0.589.
• Each ADS represents six ordinary shares of Adaptimmune Therapeutics.
• The sale was part of a 'Sell to Cover' exercise implemented automatically under the company's option plan.
• After the sale, Lunger retains 7,510 ADSs from this transaction and also holds 163,380 ADSs and options covering 10,135,962 ordinary shares.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when stock options vest.

Comparison to Industry Standards

• Executive stock sales to cover taxes are a common practice across the biotechnology industry.
• Similar transactions are regularly reported by executives at companies like Kite Pharma, Juno Therapeutics, and bluebird bio, all of which also utilize stock-based compensation.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.
• The sale does not impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Adaptimmune Therapeutics, ADS, American Depositary Shares, stock options, share sale, insider trading, Form 4, tax obligations, John Lunger, RSU